OXFORD

ORIGINAL MANUSCRIPT

MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via *EGFR* regulation

Toshinaga Suto, Takehiko Yokobori*, Reina Yajima, Hiroki Morita, Takaaki Fujii, Satoru Yamaguchi, Bolag Altan, Souichi Tsutsumi, Takayuki Asao and Hiroyuki Kuwano

Department of General Surgical Science, Graduate School of Medicine, Gunma University, 3-39-22 Showamachi, Maebashi 371-8511, Japan

*To whom correspondence should be addressed. Tel: +81-027-220-8224; Fax: +81-027-220-8230; Email: bori45@gunma-u.ac.jp

Abstract

MicroRNA-7 (*miR-7*) has been reported to be a tumor suppressor in all malignancies including colorectal cancer (CRC). However, its significance for CRC clinical outcomes has not yet been explored. The potential for *miR-7* to act as a tumor suppressor by coordinately regulating the epidermal growth factor receptor (*EGFR*) signaling pathway at several levels was examined. We investigated the tumor inhibitory effect of *miR-7* in CRC, with particular focus on the relationship between *miR-7* and the *EGFR* pathway. Quantitative reverse transcription–PCR was used to evaluate *miR-7* expression in 105 CRC cases to determine the clinicopathologic significance of this miRNA. The regulation of *EGFR* by *miR-7* was examined with *miR-7* precursor-transfected cells. Furthermore, we investigated whether *miR-7* suppresses proliferation of CRC cells in combination with cetuximab, a monoclonal antibody against *EGFR*. Multivariate analysis indicated that low *miR-7* expression was an independent prognostic factor for poor survival ($P = 0.0430$). *In vitro* assays showed that *EGFR* and *RAF-1* are direct targets of *miR-7*, which potently suppressed the proliferation of CRC cells, and, interestingly, that the growth inhibitory effect of each of these was enhanced by cetuximab. *miR-7* is a meaningful prognostic marker. Furthermore, these data indicate that *miR-7* precursor, alone or in combination with cetuximab, may be useful in therapy against CRC.

Introduction

Over 1.2 million new cases of colorectal cancer (CRC) are diagnosed worldwide every year, and CRC accounts for 8% of cancer deaths ([1]). In recent years, the incidence of CRC and associated mortality have dramatically increased in Japan ([2]). According to the 2008 edition of Global Cancer Facts & Figures, CRC is globally the third and fourth most common cause of death from a malignant neoplasm among women and men, respectively. Surgery and administration of anticancer drugs, such as oxaliplatin, have been the conventional treatments for CRC. Recently, targeted molecular treatments using antibodies, such as anti-vascular endothelial growth factor (*VEGF*) antibody and

anti-epidermal growth factor receptor (*EGFR*) antibody, have also been employed. Colon cancer chemotherapy can therefore involve traditional anticancer agents, which have non-specific cytotoxic effects, and/or agents that target specific molecules and block specific intracellular signaling pathways, with both approaches playing an important role in improving prognosis and extending the lifespans of patients ([3–6]).

The EGF receptor, which is a member of the ErbB receptor family, regulates important processes, such as cell proliferation, differentiation and development ([7–10]). It has been reported to be overexpressed in a variety of solid tumors,

Abbreviations

EGFR	epidermal growth factor receptor
miR-7	microRNA-7
UTR	untranslated region.
CRC	colorectal cancer.

including colorectal tumors, and overexpression has been found to be associated with tumor progression, resistance to chemotherapy and radiation therapy and poor prognosis (7,8). Therefore, important therapeutics used in clinical practice include antibodies targeting *EGFR* and its downstream signaling effectors and low-molecular-weight compounds that inhibit signal transduction (11–13). Anti-*EGFR* antibodies have been used to treat CRC. However, tumors can develop resistance to these agents, limiting their clinical effectiveness (14). Resistance can be caused by mutations affecting *EGFR* downstream signaling and can be acquired during treatment (14). New therapeutic tools are currently being sought to help overcome this resistance.

A microRNAs (miRNAs) are non-coding RNAs of 21–23 nucleotides in length. miRNAs bind to complementary sequences in the 3′-untranslated regions (UTRs) of target mRNAs and inhibit translation. miRNAs are involved in cancer growth, differentiation, proliferation and apoptosis (15). We focused on microRNA-7 (*miR-7*), which has been reported to target *EGFR in vitro* (16). Rai *et al.* determined that *miR-7* targets not only but also v-*raf-1* murine leukemia viral oncogene homolog 1 (*RAF-1*), a gene downstream of. As such, *miR-7* regulation might help overcome the resistance of tumors to *EGFR* inhibition therapies that are currently used in clinical practice (16).

The objectives of our study were to elucidate the clinical significance of *miR-7* expression in clinical specimens of CRC and to perform functional analysis of *miR-7* by using a CRC cell line. In our study, *miR-7* expression in these clinical specimens was measured, and its relationships with clinicopathological features, prognosis and *EGFR* protein expression were examined. Binding of *miR-7* to the 3′-UTR of *EGFR* mRNA and the 3′-UTR of *RAF-1* mRNA was analyzed by using a luciferase assay. Three CRC cell lines were used to determine the regulatory effects of *miR-7* on cell proliferation, expression of genes downstream of and cetuximab sensitivity.

Materials and methods

Patients and sample collection

All clinical CRC samples (*n* = 105) in this study were used in accordance with institutional guidelines and the Helsinki Declaration after obtaining written informed consent from all participants. All patients underwent resection of the primary tumor at the Department of General Surgical Science of Gunma University Hospital in Japan between 1999 and 2009. All patients had a clear histologic diagnosis of CRC; the diagnoses were based on the clinicopathological criteria described by the Japanese Society for Cancer of the Colon and Rectum (http://www.jsccr.jp/en/index.html). All patients were closely followed and were assessed every 3 months. The follow-up periods ranged from 0.7 months to 11 years, with a mean of 6 years. All sample data, including age, gender, histology, tumor size and depth, lymphatic invasion, vascular invasion, lymph node metastasis, liver metastasis, peritoneal dissemination, distant metastasis and clinical stage, were obtained from the clinical and pathologic records and are summarized in Table I.

The resected cancer tissues and adjacent non-cancerous tissues were immediately cut, frozen in liquid nitrogen and stored at –80°C until RNA and DNA were extracted. Total RNA was extracted by using the miRNeasy Mini kit (Qiagen) in accordance with the manufacturer's instructions.

Evaluation of miR-7 expression in clinical samples

For quantitative real-time reverse transcriptase–PCR of *miR-7*, cDNA was synthesized from 10 ng of total RNA by using the TaqMan MicroRNA Reverse Transcription Kit and specific stem-loop reverse transcription primers (Applied Bio- systems, Carlsbad, CA) according to the manufacturer's protocol. PCR was performed in a LightCycler™ 480 System (Roche, Basel, Switzerland). The 10 μl PCR reaction included 0.67 μl of reverse transcription products, 1× TaqMan Universal PCR master mix and 1 μl of primers and probe mix included in the TaqMan miRNA assay kit. The reactions were incubated in 96-well optical plates at 95°C for 10 min, followed by 45 cycles at 95°C for 15 s and 60°C for 10 min. The expression levels of *miR-7* were normalized to that of the small nuclear RNA RNU6B and analyzed by using the $2^{-\Delta\Delta Ct}$ method.

Cell lines

The HCT116 and SW480 human colon cancer cell lines, which contain v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene (*KRAS*) mutations, were used. The HT29 human colon cancer cell line harbors a *BRAF* mutation. HCT116, SW480 and HT29 cells were obtained from the American Type Culture Collection and cultured in RPMI 1640 medium (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin antibiotics (Invitrogen, Carlsbad, CA) in a humidified incubator with 5% CO_2 at 37°C.

Plasmid construction

The sequences in the 3′-UTR regions of *EGFR* mRNA and *RAF-1* mRNA that are targeted by *miR-7* were predicted with TargetScan (release 5.1), and the 3′-UTRs from human *EGFR* mRNA and *RAF-1* mRNA were amplified from the genomic DNA of normal cells. The amplified fragments were inserted into the XhoI restriction site of the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Madison, WI) by using the In-Fusion® Dry-Down PCR Cloning Kit (Clontech, Mountain View, CA). The nucleotide sequences of the plasmids were confirmed by sequencing.

Luciferase assay

HCT116 cells were seeded in 96-well plates and then cotransfected with 0.2 μg Luc-*EGFR* and *miR-7* precursor by using Lipofectamine RNAiMAX. Forty-eight hours following transfection, the activities of firefly and Renilla luciferase in cell lysates were measured by using the Dual-Glo® Luciferase Assay System (Promega) and the Fluoroskan Ascent FL (Thermo Fischer Scientific). The firefly luciferase activities produced by each vector were normalized to that of Renilla luciferase. All transfection experiments were conducted in triplicate.

Immunohistochemistry

Immunohistochemical studies of *EGFR* were conducted on formalin-fixed, paraffin-embedded surgical sections obtained from patients with CRC. The tissue sections were deparaffinized, soaked in 0.01 mol/l sodium citrate buffer and boiled in a microwave oven for 5 min at 500 W to retrieve the cellular antigens. A rabbit monoclonal antibody against *EGFR* (Cell Signaling Technology, Danvers, MA) diluted 1:100 was used as the primary antibody. All tissue sections were immunohistochemically stained with a streptavidin–biotin peroxidase complex solution (Nichirei Company, Tokyo, Japan) and counterstained with hematoxylin.

Transfection of the miR-7 precursor and miR-7 inhibitor

The pPre-miR™ miRNA Precursor hsa-miR-7-5p (*miR-7* precursor; Applied Biosystems), Pre-miR™ miRNA Precursor Molecules Negative Control (miR-nc; Applied Biosystems), mirVana® miRNA inhibitor hsa-miR-7-5p (*miR-7* inhibitor; Applied Biosystems) and mirVana® miRNA inhibitor Negative Control (miR inhibitor-nc; Applied Biosystems) were separately transfected at 20 nmol/l into HCT116, SW480 and HT29 cells by using Lipofectamine RNAiMAX (Invitrogen) in accordance with the manufacturer's instructions.

Protein expression analysis

Western blotting was used to confirm the expression of the *EGFR*, *RAF-1*, *ERK1/2*, *pAKT* and β-actin proteins in *miR-7* precursor- and *miR-7*

Table I. Relationship between *miR-7* expression and clinicopathological features

Factors	miR-7/RNU6B		P value
	High expression	Low expression	
	n = 37	n = 68	
Age (n)			0.385
< 59	11	15	
≧59	26	53	
Gender (n)			0.724
Male	21	41	
Female	16	27	
Histology (n)			0.753
Well	12	20	
Others	25	48	
Tumor size (mm)			0.083
< 50	20	32	
≧50	17	36	
Depth			0.630
m, sm, mp	14	29	
ss, se, si	23	39	
Lymphatic invasion			0.822
Negative	8	12	
Positive	29	56	
Venous invasion			0.733
Negative	16	42	
Positive	21	26	
Lymph node metastasis			0.353
Negative	22	34	
Positive	15	34	
Liver metastasis			0.478
Negative	30	51	
Positive	7	17	
Peritoneal dissemination			0.133
Negative	37	64	
Positive	0	4	
Distant metastasis			0.662
Negative	36	65	
Positive	1	3	
Stage			0.627
I, II	15	31	
III, IV	22	37	

Well, well differentiated.

inhibitor-transfected cells. Total protein (40 µg) was electrophoresed and then electrotransferred at 200 mA for 180 min at 4°C. These proteins were detected by using an anti-*EGFR* rabbit monoclonal antibody (1:1000; Cell Signaling Technology), an anti-*ERK1/2* rabbit monoclonal antibody (1:1000; Cell Signaling Technology), a rabbit monoclonal antibody against *Raf-1* (1:1000; Origene, Rockville, MD) and an anti-*pAKT* rabbit monoclonal antibody (1:1000; Cell Signaling Technology); an anti-β-actin mouse monoclonal antibody (1:1000; Sigma–Aldrich, St Louis, MO) served as a control. Bands and band intensities were detected and calculated, respectively, by using ECL Prime Western Blotting Detection Reagent and an Image Quant LAS 4000 (GE Healthcare Life Sciences).

Proliferation assay

Analysis of proliferation was performed on cells that had been transfected with either the *miR-7* precursor or the *miR-7* inhibitor. The cells were plated in 96-well plates in 100 µl of medium at ~5000 cells per well. To quantitate cell viability with the Cell Counting Kit-8 assay (CCK-8; Dojindo

Laboratory, Tokyo, Japan), 10 µl of the cell counting solution was added to each well after 0, 24, 48 or 72 h, and then the plates were incubated at 37°C for 2 h. The cell proliferation rate was then determined by measuring the absorbance of the well at 450 nm with the reference wavelength set at 650 nm. The absorbances were measured with a microtiter plate reader (Molecular Devices, Sunnyvale, CA).

Regulation of the cetuximab sensitivity of CRC cells by miR-7

HCT116, SW480 and HT29 cells, 5000 cells per well, were seeded in 96-well plates and then treated with 0, 0.01, 0.1, 1, 10, 20, 50 or 100 µg/ml cetuximab for 96 h. For each dose, cells from one plate were harvested to determine the absorbance value. Viable cells were counted 96 h posttreatment with the CCK-8 assay by measuring the absorbances of the samples at 450 nm, with the reference wavelength set at 650 nm.

Statistical analysis

The differences between two groups were estimated by using the *t*-test, the chi-square test and the repeated measures analysis of variance test. Kaplan–Meier curves were generated for overall survival, and statistical significance was determined by using the log-rank test. A probability value of <0.05 was considered significant. In addition, univariate and multivariate survival analyses were performed using Cox's proportional hazards model. All statistical analyses were performed with JMP5.0 software (SAS Institute Incorporated, Cary, NC).

Results

### The clinicopathological significance of miR-7 expression in CRC

The expression levels of *miR-7* in cancerous tissues (T) were higher than those in adjacent, non-cancerous tissues (N) ($P < 0.001$; Figure 1A). In this study, the receiver operating characteristic curve determined the cutoff point. Cancerous tissue below the cutoff point for *miR-7* expression of 3.21, normalized to expression of the U6 small nuclear RNA *RNU6B*, was assigned to the low-expression group (n = 68), whereas cancerous tissue with an expression level above the cutoff point was assigned to the high-expression group (n = 37). Patients in the low-*miR-7*-expression group had a significantly poorer prognosis than those in the high-*miR-7*-expression group ($P = 0.0489$; Figure 1B). In addition, the clinicopathological factors of age, gender distribution, histology, tumor depth, lymphatic or venous invasion, lymph node, liver, or distant metastasis, peritoneal dissemination, or clinical staging were not significantly different between these two groups (Table I). However, tumor size in the low-*miR-7*-expression group showed a non-significant increase ($P = 0.083$) over that seen in the high-*miR-7*-expression group (Table I). The results of univariate and multivariate Cox proportional hazards regression analyses for overall survival are shown in Supplementary Table 1, available at *Carcinogenesis* Online. Multivariate analysis indicated that low expression of *miR-7* was an independent and significant prognostic factor for survival (relative risk: 0.82; 95% confidence interval: 0.54–0.94; $P = 0.0430$; Supplementary Table 1, available at *Carcinogenesis* Online).

miR-7 regulates EGFR and RAF-1 in CRC cells

By using *in silico* miRNA target prediction tools, such as TargetScan, we identified *miR-7* binding sites in the 3′-UTRs of transcripts encoding *EGFR* and *RAF-1* (Figure 2A and C). To investigate miRNA binding and repression, we performed a luciferase reporter assay with a vector in which the 3′-UTR sequences of *EGFR* mRNA and *RAF-1* mRNA were inserted downstream of the luciferase reporter gene (Luc-*EGFR*, Luc-*RAF-1*). The luciferase

Figure 1. Clinical significance of *miR-7* expression in **CRC** samples. (**A**) *miR-7* expression in cancerous (T) (*n* = 105) and adjacent non-cancerous (N) (*n* = 105) tissues from CRC patients assessed by TaqMan reverse transcription–PCR. All data were normalized to RNU6B. Horizontal lines indicate the means (*P* < 0.001). (**B**) Kaplan–Meier curves according to *miR-7* expression levels in CRC patients (*P* = 0.0489).

Figure 2. *EGFR* and *RAF-1* expression is directly suppressed by *miR-7* in CRC. (**A**) *miR-7* binding sites in the *EGFR* 3′-UTR. Putative conserved target sites in the 3′-UTR were identified using *in silico* miR target prediction tools. (**B**) Luciferase assays of pre-*miR-7*-transfected HCT116 cells. The error bars represent the SD from eight replicates. Left bar: *EGFR* 3′-UTR luciferase vector only. Middle bar: *EGFR* 3′-UTR luciferase vector + miR-nc. Right bar: *EGFR* 3′-UTR luciferase vector + *miR-7* precursor (*P* < 0.001). (**C**) *miR-7* binding sites in the *RAF-1* 3′-UTR. Putative conserved target sites in 3′-UTR were identified using *in silico* miR target prediction tools. (**D**) Luciferase assays of pre-*miR-7*-transfected HCT116 cells. The error bars represent the SD from eight replicates. Left bar: *RAF-1* 3′-UTR luciferase vector only. Middle bar: *RAF-1* 3′-UTR luciferase vector + miR-nc. Right bar: *RAF-1* 3′-UTR luciferase vector + *miR-7* precursor (*P* < 0.001).

activities of Luc-*EGFR* and Luc-*RAF-1* were both significantly reduced when compared with that of the negative control in transient cotransfection of HCT116 cells with *miR-7* precursor (*P* < 0.001, *P* < 0.001, respectively; Figure 2B and D). These data suggest that the 3′-UTRs of both *EGFR* and *RAF-1* are direct functional targets of *miR-7*.

miR-7 and EGFR protein expression in clinical samples

For each frozen tissue sample used to measure miR-7 levels in colorectal tumors and adjacent non-cancerous tissue, representing 105 patients with CRC, there were matching, adjacent formalin-fixed, paraffin-embedded surgical sections from the same tumor the association between *miR-7* and *EGFR* protein expression in clinical samples, we used immunohistochemistry sections of the formalin-fixed, paraffin-embedded samples, which were then divided into groups based on a score of *EGFR* protein expression. Samples were further classified according to the staining patterns in the tumor cell membranes as either incomplete staining, i.e. tumor cells were stained in only part of their membrane, and complete staining, i.e. tumor cells displayed a circumferential staining of the entire tumor cell membrane (17). The following scoring system for assessing *EGFR* immunostaining was used: score 0 = no staining or unspecific staining of tumor cells; score 1 = weak (intensity) and incomplete staining (quality) of > 10% of tumor cells (quantity); score 2 = moderate and complete staining of > 10% of tumor cells; score 3 = strong and complete staining of > 10% of tumor cells. Representative examples for the different scores are shown in Supplementary Figure 1A, available at *Carcinogenesis* Online. The expression of

miR-7 was significantly increased in the *EGFR* expression-negative group (score 0) compared with the *EGFR* expression-positive group (score 1–3) (mean ± SEM: *EGFR* expression-negative group = 6.01±0.58; *EGFR* expression-positive group = 2.19±0.38; *P* = 0.043; Supplementary Figure 1B, available at *Carcinogenesis* Online).

Expression of EGFR, RAF-1, ERK1/2 and pAKT is suppressed by miR-7 in vitro

We used quantitative reverse transcription–PCR to confirm that *miR-7* expression in cells transfected with *miR-7* precursor was significantly higher than that in both untreated cells ('Parent' in Figures 2–5) and cells transfected with miR-nc (*P* < 0.001, Supplementary Figure 2, available at *Carcinogenesis* Online). We also determined that *miR-7* expression in cells transfected with *miR-7* inhibitor was significantly lower than that in either untreated cells or cells transfected with the miR inhibitor-nc (*P* < 0.001, Supplementary Figure 3, available at *Carcinogenesis* Online). To determine whether *miR-7* suppresses *EGFR* expression and downstream signaling events in the CRC cell lines HCT116, SW480 and HT29, cell lysates of transfected cells were analyzed by Western blotting. They were then compared with untreated cells and miR-nc-treated cells. In HCT116 and SW480 cell lines (*KRAS* mutation), the expression of *EGFR*, *RAF-1*, *pAKT* and *ERK1/2* was downregulated in cells transfected with *miR-7* precursor (Figure 3A and C), while the expression of *EGFR*, *RAF-1*, *pAKT* and *ERK1/2* in cells transfected with *miR-7* inhibitor was upregulated relative to the expression in untreated cells and cells transfected with the miR inhibitor-nc (Figure 3B and D). However, in the HT29 cell line (*BRAF* mutation), the expression of *EGFR*, *RAF-1* and *pAKT* was downregulated in cells transfected

Figure 3. Expression of *EGFR*, *Raf-1*, *pAKT* and *ERK1/2* is suppressed by *miR-7* in **CRC** cells. Western blotting of *EGFR*, *Raf-1*, *pAKT* and *ERK1/2* protein in *miR-7* precursor-transfected HCT116 cells (**A**), SW480 cells (**C**) and HT29 cells (**E**). Western blotting of *EGFR*, *Raf-1*, *pAKT* and *ERK1/2* protein in *miR-7* inhibitor-transfected HCT116 cells (**B**), SW480 cells (**D**) and HT29 cells (**F**). Protein levels were normalized with respect to beta-actin.

with the *miR-7* precursor, while *ERK1/2* expression was upregulated (Figure 3E). These cells also upregulated the expression of *EGFR*, *RAF-1*, *pAKT* and *ERK1/2* upon transfection with miR-7 inhibitor relative to the expression in untreated cells and cells transfected with miR inhibitor-nc (Figure 3F).

miR-7 regulates proliferation in HCT116, SW480 and HT29 cells

We analyzed the proliferation of HCT116, SW480 and HT29 cells that had been transfected with either miR-7 precursor or miR-7 inhibitor. In HCT116 and SW480 cells, the proliferation rate of miR-7 precursor-treated cells was significantly lower than that of untreated cells (*P* < 0.001; Figure 4A and B). In contrast, the proliferation rate of miR-7 inhibitor-treated cells was significantly higher than that of untreated cells (*P* < 0.001; Figure 4A and B). In HT29 cells, the proliferation rate of miR-7 precursor-treated cells was not significantly different from that of untreated cells (*P* = 0.0636; Figure 4C). Similarly, there was no significant difference between the proliferation rates of miR-7 inhibitor-treated cells and untreated cells (*P* = 0.2151; Figure 4C).

miR-7 regulates cetuximab sensitivity in cetuximab-resistant HCT116 and SW480 cells with a KRAS mutation and HT29 cells with a BRAF mutation

To determine if cetuximab, an *EGFR*-targeted antibody, enhances the antitumor efficacy of miR-7 in CRC cells, we treated HCT116, SW480 and HT29 cells with cetuximab and analyzed proliferation in cells that received only cetuximab treatment and cells that were transfected with either miR-7 precursor or miR-nc after cetuximab treatment. HCT116 and SW480 colon cancer cells carry *KRAS* mutations and, as such, are resistant to cetuximab. Whereas untreated cells and miR-nc-treated cells were highly resistant to cetuximab, the miR-7 precursor-treated cells responded to this drug (*P* < 0.001; Figure 5A and B). However, in HT29 cells with a *BRAF* mutation, there was no change in the sensitivity to cetuximab in cells treated with the miR-7 precursor (*P* = 0.8584; Figure 5C).

Discussion

In this study, we determined that the expression of miR-7 in primary CRC is higher than in normal colorectal tissues; however, a low level of miR-7 expression is associated with cancer progression and poor prognosis. We also determined that miR-7 regulates proliferation and cetuximab sensitivity via *EGFR* suppression.

We focused on miR-7, which has been reported to target *EGFR in vitro* (16). Rai *et al.* demonstrated that miR-7 targets not only *EGFR* but also *RAF-1*, a gene downstream of *RAS*. Mir-7 targets many other genes besides those analyzed in this study. Induction of miR-7 might overcome resistance of tumors to therapies that inhibit *EGFR* (16,18). Cetuximab is one of the targeted molecular drugs that have recently been used to treat patients with CRC. However, unresolved issues with this drug persist, such as acquired treatment resistance caused by mutations in *KRAS* and *BRAF*, both of which participate in the *EGFR* signaling pathway (19). Cetuximab is known to have low effectiveness in patients with either *KRAS* or *BRAF* mutations; this feature warrants limitations on its use (19). We examined how treatment with miR-7 changes cetuximab sensitivity in cetuximab-resistant HCT116 and SW480 cells, which harbor *KRAS* mutations, and HT29 cells, which harbor a *BRAF*

mutation. Cetuximab treatment did not reduce proliferation of the parent HCT116 and SW480 cells, but cetuximab sensitivity increased in miR-7 precursor-treated HCT116 and SW480 cells. Since miR-7 does not target *EGFR* alone, it would be difficult to markedly increase cetuximab sensitivity by treatment with miR-7. miR-7 has been reported to bind to the 3′-UTR in the mRNA of not only *EGFR*, but also to that of *RAF-1*, a gene downstream of *KRAS*, and inhibit translation (16). Similarly, in this study, *RAF-1*, which is downstream of *EGFR*, is also a potential target of miR-7 (Figure 2). In HT29 cells with a *BRAF* mutation, there was no change in the sensitivity to cetuximab in cells treated with the miR-7 precursor. When *KRAS* and *BRAF* are not mutated, *KRAS* signals to *ERK1/2* through *BRAF* rather than *RAF-1*. When *KRAS* is mutated, however, KRAS signaling switches from *BRAF* to *RAF-1*, and the *EGFR* pathway is hyperactivated. When *BRAF* is mutated, the *EGFR* pathway is also hyperactivated, but instead by BRAF-dependent activation of *ERK1/2* (20). In HT29 cells that do not have mutated *KRAS*, *EGFR* signaling occurs through *BRAF*, and as such the combination effect of cetuximab with *miR-7* that is targeted to *RAF-1* would not be expected to occur.

miR-7 inhibits *EGFR* signaling that may regulate the growth capacity and cetuximab sensitivity of colon cancer cells. When there is a mutation in *BRAF* in colon cancer, a combined effect of an *EGFR* inhibitor and *miR-7* does not occur, but in cancers that have both low *miR-7* expression and *KRAS* mutations, *miR-7* administration may be a strategy to overcome resistance to therapeutic agents.

We showed that expression of *miR-7* was increased in CRC specimens. In lung cancer, *EGFR* mutations have also been reported to induce *miR-7* expression (16).

When *EGFR* activation is caused by a driver mutation, the effects of changes in *EGFR* expression levels are small in CRC, which is in contrast to the effects of EGFR in lung cancer, suggesting that the signaling mechanisms may differ across cancer types (21). This finding suggests that activation of *EGFR* signaling and induction of *miR-7* expression might be specific to the cancer type. Our study also showed that *miR-7* expression was significantly lower in the clinical specimens of patients with CRC who had positive *EGFR* protein expression than in the clinical specimens of those with negative expression. An *in vitro* analysis revealed that *EGFR* and *RAF-1* translation were inhibited by the binding of *miR-7* to the 3′-UTR of *EGFR* mRNA and *RAF-1* mRNA in a CRC cell line. Our data suggest that *miR-7* might not be induced by *EGFR* signaling and that *miR-7* inhibits *EGFR* signaling. Thus, a low level of *miR-7* expression in CRC lesions is thought to be associated with the progression of cancer and a poor prognosis. From our *in vitro* data, it is expected that the cetuximab sensitivity in primary CRC with high *miR-7* expression is higher than in cases of low *miR-7* expression, even if they have a *KRAS* mutation. *miR-7* might be a useful cetuximab sensitivity marker in CRC.

In conclusion, the low expression of *miR-7* correlated with cancer progression and poor prognosis. Low expression of *miR-7* could be a useful prognostic marker for CRC. In addition, *miR-7* regulates CRC cell proliferation and resistance to cetuximab *in vitro*. Finally, *miR-7* might be a promising candidate for targeted therapy in patients with CRC whose tumors are resistant to *EGFR*-directed antibodies.

Supplementary material

Supplementary Table 1 and Figures 1–3 can be found at http://carcin.oxfordjournals.org/

Figure 4. Proliferation potency is suppressed by *miR-7* in HCT116, SW480 and HT29 cells. (**A** and **B**) In HCT116 and SW480 cells, the proliferation rate of *miR-7* precursor-treated cells was suppressed in comparison with that of untreated cells. In contrast, the proliferation rate of *miR-7* inhibitor-treated cells was significantly higher than that of untreated cells. (**C**) In HT29 cells, the proliferation rate of *miR-7* precursor-treated cells was not significantly different from that of untreated cells. Similarly, there was no difference between the proliferation rates of *miR-7* inhibitor-treated and untreated cells. The data represent the means ± SD of five replicates.

Figure 5. *miR-7* inhibits the proliferation of the **CRC** cell line *EGFR* **in combination with cetuximab.** To determine the cetuximab sensitivity of the cetuximab-resistant (**A**) HCT116 and (**B**) SW480 cells with *KRAS* mutations and (**C**) HT29 cells with a *BRAF* mutation, 5000 cells per well were seeded in 96-well plates and then treated with 0, 0.01, 0.1, 1, 10, 20, 50 or 100 µg/ml cetuximab for 96 h. Viable cells were counted 96 h posttreatment with the CCK-8 assay. The results are presented as means ±SD of three replicates.

Funding

References

1. Jemal, A. et al. (2011) Global cancer statistics. CA. Cancer J. Clin., 61, 69–90.
2. Center, M.M. et al. (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol. Biomarkers Prev., 18, 1688–1694.
3. Hurwitz, H. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350, 2335–2342.
4. Saltz, L.B. et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol., 26, 2013–2019.
5. Jonker, D.J. et al. (2007) Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med., 357, 2040–2048.
6. Van Cutsem, E. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 360, 1408–1417.
7. Spano, J.P. et al. (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol., 16, 102–108.
8. Bianco, R. et al. (2007) Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol., 39, 1416–1431.
9. Prigent, S.A. et al. (1992) The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res., 4, 1–24.
10. Salomon, D.S. et al. (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 183–232.
11. Saltz, L.B. et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol., 22, 1201–1208.
12. Cunningham, D. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 351, 337–345.
13. Hanna, N. et al. (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol., 24, 5253–5258.
14. Misale,S. et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486, 532–536.
15. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.
16. Rai, K. et al. (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther., 10, 1720–1727.
17. Atkins, D. et al. (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem., 52, 893–901.
18. Webster, R.J. et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J. Biol. Chem., 284, 5731–5741.
19. Razis, E. et al. (2014) EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J. Cancer Res. Clin. Oncol., 140, 737–748.
20. Dhomen, N. et al. (2007) New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev., 17, 31–39.
21. Chou, Y.T. et al. (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res., 70, 8822–8831.